Press Release: Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Dow Jones11-13
   -- NDV-01 CMC program on track to submit the IND by year-end 2026, with 
      initiation of the registrational Phase 3 SPECTRUM program upon IND 
      clearance 
 
   -- Long-term extension NDV-01 Phase 2 data demonstrate continued durability 
      of response: 86% of 12-month complete responders remained in complete 
      response at 18 months, with no Grade >=3 treatment-related adverse events 
      or discontinuations 
 
   -- Registrational Phase 3 program renamed SPECTRUM; two independent 
      registrational pathways in NMIBC remain unchanged 
 
   -- Cash, cash equivalents and short-term investments of approximately $202.1 
      million as of September 30, 2026, expected to fund operations through 
      2029 

CORAL GABLES, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, including 18-month results from the NDV-01 Phase 2 study, the registrational Phase 3 SPECTRUM program, and continued progress toward the planned year-end 2026 Investigational New Drug (IND) submission for NDV-01 and sepranolone.

"Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program," said Sergio Traversa, Chief Executive Officer of Relmada Therapeutics.

"Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability," added Bipin Dalmia, Chief Business Officer of Relmada Therapeutics. "Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance."

CMC and Manufacturing Update

NDV-01: NDV-01 CMC program is on track for IND submission by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through completion of the Phase 3 SPECTRUM program.

Sepranolone: The Company is finalizing the stability testing of the pre-filled syringe (PFS) delivery system to enable sepranolone IND submission, which is on track for year-end 2026. We expect to start the Phase 2b trial in Prader-Willi Syndrome upon IND clearance.

NDV-01 Clinical Update

Phase 2 Study: Initial 18-month results from the ongoing Phase 2 TRGC-011 study of NDV-01 in high-risk NMIBC continue to support extended durability of NDV-01 complete responses and continued favorable tolerability profile.

   -- Initial 18-month durability results: 23 patients in complete response 
      $(CR)$ at 12 months continued into the long-term extension (LTE). 86% 
      (12/14) of evaluable patients who reached 18 months remained in CR. In 
      the BCG-unresponsive subgroup, 11 patients continued into the LTE, and 
      88% (7/8) of evaluable patients who reached 18 months remained in CR. Two 
      BCG-naïve patients (T1 at study entry) progressed to muscle-invasive 
      disease (T2a) at the Month 15 assessment. 
 
   -- Updated 12-month efficacy results: Among 51 evaluable patients, the 
      anytime CR rate was 94% (48/51) and the 12-month CR rate was 77% (24/31). 
      In the BCG-unresponsive subgroup, the anytime CR rate was 96% (22/23) and 
      12-month CR rate was 73% (11/15). Through 12-months, both 
      progression-free and cystectomy-free survival was 100%. 
 
   -- Safety and tolerability: To date, there were no Grade >=3 
      treatment-related adverse events (TRAEs), no treatment-related serious 
      adverse events, and no treatment-related discontinuations. 

Phase 3 SPECTRUM Program: The NDV-01 Phase 3 program remains unchanged and is designed to pursue two independent registrational pathways in NMIBC:

   1. A single-arm study in second-line (2L) high-risk BCG-unresponsive 
      carcinoma in situ (CIS) +/- Ta/T1 (Cohort 2UC), together with a separate 
      single-arm 2L high-risk BCG-unresponsive Ta/T1 w/o CIS exploratory cohort 
      (Cohort 2UP). 
 
   2. A randomized study evaluating NDV-01 as adjuvant therapy following 
      transurethral resection of bladder tumor (TURBT) versus observation in 
      low-grade intermediate-risk NMIBC (Cohort IRA). 

The Company has changed the name of its Phase 3 program from RESCUE to SPECTRUM to better reflect the potential breadth of NDV-01 across the entire NMIBC disease spectrum. Clinical trial sites are engaged and preparing to initiate patient enrollment upon IND clearance.

Anticipated Upcoming Milestones

NDV-01:

   -- NDV-01 United States IND submission -- By year-end 2026 
 
   -- NDV-01 Phase 3 SPECTRUM program initiation -- Upon IND clearance 

Sepranolone:

   -- Sepranolone United States IND submission -- By year-end 2026 
 
   -- Sepranolone Phase 2b initiation in Prader-Willi Syndrome -- Upon IND 
      clearance 

Financial Results

Third Quarter 2026 Financial Results

   -- Research and development expense for the three months ended September 30, 
      2026, totaled $9.2 million, compared to $4.0 million for the three months 
      ended September 30, 2025, an increase of $5.2 million. The increase was 
      primarily attributable to higher NDV-01 and sepranolone study preparation 
      costs, increased manufacturing and drug storage costs and higher employee 
      compensation, partially offset by lower stock-based compensation. 
 
   -- General and administrative expense for the three months ended September 
      30, 2026, totaled $3.9 million compared to $6.3 million for the three 
      months ended September 30, 2025, a decrease of approximately $2.4 
      million. The decrease was primarily driven by lower stock-based 
      compensation and lower stock appreciation rights expense, partially 
      offset by higher employee compensation and consulting services. 
 
   -- Net cash used in operating activities for the three months ended 
      September 30, 2026, totaled $12.6 million compared to $6.7 million for 
      the three months ended September 30, 2025. 
 
   -- The net loss for the three months ended September 30, 2026, was $13.9 
      million, or $0.12 per basic and diluted share, compared with a net loss 
      of $10.1 million, or $0.30 per basic and diluted share, for the three 
      months ended September 30, 2025. 
 
   -- As of September 30, 2026, the Company's cash, cash equivalents, and 
      short-term investments totaled $202.1 million, compared to cash, cash 
      equivalents, and short-term investments of approximately $93.0 million at 
      December 31, 2025. 
 
   -- The Company's current cash, cash equivalents, and short-term investments 
      as of September 30, 2026, are expected to provide sufficient resources to 
      fund Company operations through 2029, including completion of the two 
      registrational cohorts of the NDV-01 Phase 3 SPECTRUM program. 
 
   -- The Company had 106,694,846 shares outstanding, as of November 10, 2026. 

Nine Months Ended September 30, 2026 Financial Results

   -- Research and development expense for the nine months ended September 30, 
      2026, totaled $25.7 million, compared to $18.8 million for the nine 
      months ended September 30, 2025, an increase of $6.9 million. The 
      increase was primarily attributable to increased manufacturing and drug 
      storage costs, higher employee compensation and higher stock appreciation 
      rights expense, partially offset by lower study costs and lower 
      stock-based compensation. 
 
   -- General and administrative expense for the nine months ended September 
      30, 2026, totaled $21.9 million compared to $20.0 million for the nine 
      months ended September 30, 2025, an increase of approximately $1.9 
      million. The increase was primarily driven by higher employee 
      compensation, stock appreciation rights expense and consulting services, 
      partially offset by lower stock-based compensation. 
 
   -- Net cash used in operating activities for the nine months ended September 
      30, 2026, totaled $37.3 million compared to $31.2 million for the nine 
      months ended September 30, 2025. 
 
   -- The net loss for the nine months ended September 30, 2026, was $45.8 
      million, or $0.44 per basic and diluted share, compared with a net loss 
      of $37.5 million, or $1.16 per basic and diluted share, for the nine 
      months ended September 30, 2025. 

Conference Call and Webcast Information

Relmada will host a conference call and webcast today at 4:30 PM ET to discuss recent business progress and financial results.

Date: Thursday, November 12, 2026 at 4:30 PM ET

Participant Dial-in (US): 1-800-717-1738

Participant Dial-in (International): 1-646-307-1865

Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.

About NDV-01

NDV-01 is a novel, sustained-release, intravesical co-formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The formulation is engineered to provide prolonged bladder retention and sustained drug release for up to 10 days. By forming a soft intravesical matrix, NDV-01 is designed to increase local drug exposure while limiting systemic toxicity. The treatment can be administered conveniently in an office setting in under 5 minutes without the need for anesthesia or specialized equipment. NDV-01 is encompassed by multiple patent applications that if issued, could provide protection until 2047.

About the NDV-01 Phase 3 SPECTRUM Registrational Pathways:

Relmada has received written FDA feedback confirming alignment on two registrational pathways for NDV-01, including study design, patient populations, and primary endpoints. The Company expects to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM program upon IND clearance.

About NMIBC

NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence rates (50--80% over 5 years) and disease progression in a subset of these patients. With 63,000 incident NMIBC cases per year in the U.S. and limited treatment options, the market opportunity is significant. High-risk BCG-unresponsive disease represents the biggest unmet need in NMIBC, with limited and suboptimal bladder-sparing treatment options. While four therapies are FDA-approved for first line BCG-unresponsive disease, there are no approved therapies in the second line or later. Intermediate-risk NMIBC in the adjuvant setting has no currently approved therapies and patients with recurrence must undergo repeated surgical resections. NDV-01 has the potential to serve as a foundational intravesical therapy across the NMIBC disease spectrum.

About Sepranolone and GABA Modulation

Sepranolone, a synthetic isoallopregnanolone, selectively modulates GABA(A) receptors by antagonizing allopregnanolone $(ALLO)$, without disrupting GABA signaling. It targets disorders linked to excess GABAergic activity such as Prader-Willi syndrome (PWS), Tourette syndrome, and obsessive-compulsive disorder (OCD). More than 335 patients have been treated with sepranolone in clinical trials to date, with a favorable safety profile. The Company is on track to submit the sepranolone IND by year-end 2026 and expects to initiate the Phase 2 study in Prader-Willi syndrome upon IND clearance.

About Prader-Willi Syndrome (PWS)

PWS is a rare genetic disorder caused by chromosomal deletions on chromosome 15, leading to neurodevelopmental and behavioral complications. Global prevalence is estimated to be 350,000-400,000 patients. Current treatments address symptoms but do not modify the underlying neurobehavioral pathology.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Forward-Looking Statements:

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "if", "may", "expects", "anticipates", "believes", "will", "will likely result", "will continue", "plans to", "potential", "promising", and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada's product candidates to fail to progress, potential for Phase 2 NDV-01 data to fail to continue to deliver positive results supporting further development, potential for clinical trials to fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of interim or top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, potential changes to the design, size or timing of the Phase 3 SPECTRUM studies, including as a result of updated treatment guidelines or third-party clinical data, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to successfully execute manufacturing and CMC activities for NDV-01 and/or sepranolone, including GMP manufacture of clinical trial material, manufacturing scale-up, process validation, timing of completion of manufacturing activities, and regulatory acceptance of manufacturing-related submissions, failure to secure adequate NDV-01 and/or sepranolone drug supply, failure of pending patent applications to result in issued patents, or issued patents being challenged and invalidated by third parties or not providing us with any competitive advantages, the Company's cash runway and sufficiency of the Company's cash resources and uncertainties inherent in estimating the Company's cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list.

Investor Contact:

Brian Ritchie

LifeSci Advisors

britchie@lifesciadvisors.com

Media Inquiries:

Corporate Communications

media@relmada.com

 
 
                     Relmada Therapeutics, Inc. 
                Condensed Consolidated Balance Sheets 
 
                                        As of 
                                    September 30,       As of 
                                        2026        December 31, 
                                     (Unaudited)         2025 
                                    -------------   ------------- 
             Assets 
Current assets: 
  Cash and cash equivalents         $   5,720,325   $   3,496,540 
  Short-term investments              196,402,988      89,509,710 
  Other receivable                         10,912              -- 
  Prepaid expenses                      2,915,011         977,721 
                                     ------------    ------------ 
Total current assets                  205,049,236      93,983,971 
Other assets                              247,379          19,500 
                                     ------------    ------------ 
Total assets                        $ 205,296,615   $  94,003,471 
                                     ============    ============ 
 
  Liabilities and Stockholders' 
             Equity 
Current liabilities: 
  Accounts payable                  $   2,538,585   $   1,568,944 
  Accrued expenses                      5,237,116       4,861,583 
                                     ------------    ------------ 
Total current liabilities               7,775,701       6,430,527 
Stock appreciation rights               3,783,853       1,060,931 
                                     ------------    ------------ 
Total liabilities                      11,559,554       7,491,458 
                                     ------------    ------------ 
 
Commitments and Contingencies 
(See Note 8) 
 
Stockholders' Equity: 
   Preferred stock, $0.001 par 
   value, 200,000,000 shares 
   authorized, none issued and 
   outstanding                                 --              -- 
   Class A convertible preferred 
   stock, $0.001 par value, 
   3,500,000 shares authorized, 
   none issued and outstanding                 --              -- 
   Common stock, $0.001 par value, 
    200,000,000 and 150,000,000 
    shares authorized, 
    respectively, 106,694,846 and 
    73,333,622 shares issued and 
    outstanding, respectively             106,695          73,333 
Additional paid-in capital            937,725,893     784,705,878 
Accumulated deficit                  (744,095,527)   (698,267,198) 
                                     ------------    ------------ 
Total stockholders' equity            193,737,061      86,512,013 
                                     ------------    ------------ 
Total liabilities and 
 stockholders' equity               $ 205,296,615   $  94,003,471 
                                     ============    ============ 
 
 
                             Relmada Therapeutics, Inc. 
                   Condensed Consolidated Statements of Operations 
                                     (Unaudited) 
 
                             Three months ended             Nine months ended 
                                September 30,                 September 30, 
                         ---------------------------   --------------------------- 
                             2026           2025           2026           2025 
                         ------------   ------------   ------------   ------------ 
Operating expenses: 
  Research and 
   development           $  9,217,440   $  4,036,267   $ 25,699,073   $ 18,806,667 
  General and 
   administrative           3,878,983      6,291,079     21,870,130     19,960,421 
                          -----------    -----------    -----------    ----------- 
Total operating 
 expenses                  13,096,423     10,327,346     47,569,203     38,767,088 
                          -----------    -----------    -----------    ----------- 
 
Loss from operations      (13,096,423)   (10,327,346)   (47,569,203)   (38,767,088) 
                          -----------    -----------    -----------    ----------- 
 
Other (expenses) 
income: 
  Interest/investment 
   income, net              2,274,541        247,013      5,535,697      1,008,758 
  Realized (loss) gain 
   on short-term 
   investments               (435,122)       (81,438)      (482,284)        28,717 
  Unrealized (loss) 
   gain on short-term 
   investments             (2,605,184)        70,275     (3,312,539)       212,210 
                          -----------    -----------    -----------    ----------- 
 
Total other (expense) 
 income -- net               (765,765)       235,850      1,740,874      1,249,685 
                          -----------    -----------    -----------    ----------- 
 
Net loss                 $(13,862,188)  $(10,091,496)  $(45,828,329)  $(37,517,403) 
                          ===========    ===========    ===========    =========== 
 
Loss per common share 
 -- basic and diluted    $      (0.12)  $      (0.30)  $      (0.44)  $      (1.16) 
                          ===========    ===========    ===========    =========== 
 
Weighted average number 
 of common shares 
 outstanding -- basic 
 and diluted              112,437,710     33,191,622    103,745,599     32,274,238 
                          ===========    ===========    ===========    =========== 
 
 
                              Relmada Therapeutics, Inc. 
             Condensed Consolidated Statements of Changes in Stockholders' 
                                        Equity 
                                      (Unaudited) 
 
                          Three and Nine months ended September 30, 2026 
                ------------------------------------------------------------------- 
                                         Additional 
                     Common Stock          Paid-in      Accumulated 
                ---------------------- 
                                Par 
                   Shares      Value      Capital         Deficit         Total 
                ------------  --------  ------------   -------------   ------------ 
Balance -- 
 December 31, 
 2025             73,333,622  $ 73,333  $784,705,878   $(698,267,198)  $ 86,512,013 
Stock based 
 compensation             --        --       956,186              --        956,186 
Proceeds from 
 issuance of 
 common stock, 
 net              29,474,569    29,475   150,352,510              --    150,381,985 
ATM Fees                  --        --       (65,651)             --        (65,651) 
Cashless 
 exercise of 
 pre-funded 
 warrants for 
 common stock      2,082,032     2,082        (2,082)             --             -- 
Net loss                  --        --            --     (19,051,956)   (19,051,956) 
                 -----------   -------   -----------    ------------    ----------- 
Balance -- 
 March 31, 
 2026            104,890,223   104,890   935,946,841    (717,319,154)   218,732,577 
Stock based 
 compensation             --        --       902,903              --        902,903 
ATM fees                  --        --       (66,273)             --        (66,273) 
Stock issuance 
 costs                    --        --      (199,879)             --       (199,879) 
Exercise of 
 pre-funded 
 warrants for 
 common stock      1,682,500     1,683            --              --          1,683 
Options 
 exercised            97,123        97       101,400              --        101,497 
Net loss                  --        --            --     (12,914,185)   (12,914,185) 
                 -----------   -------   -----------    ------------    ----------- 
Balance -- June 
 30, 2026        106,669,846   106,670   936,684,992    (730,233,339)   206,558,323 
Stock based 
 compensation             --        --     1,023,176              --      1,023,176 
Options 
 exercised            25,000        25        17,725              --         17,750 
Net loss                  --        --            --     (13,862,188)   (13,862,188) 
                 -----------   -------   -----------    ------------    ----------- 
Balance -- 
 September 30, 
 2026            106,694,846  $106,695  $937,725,893   $(744,095,527)  $193,737,061 
                 ===========   =======   ===========    ============    =========== 
 
 
                         Three and Nine months ended September 30, 2025 
                ----------------------------------------------------------------- 
                                       Additional 
                    Common Stock         Paid-in      Accumulated 
                -------------------- 
                               Par 
                  Shares      Value     Capital         Deficit         Total 
                -----------  -------  ------------   -------------   ------------ 
Balance -- 
 December 31, 
 2024            30,174,202  $30,174  $676,373,822   $(640,882,035)  $ 35,521,961 
Stock-based 
 compensation            --       --     3,572,769              --      3,572,769 
Issuance of 
 Restricted 
 Common Stock     3,017,420    3,017       902,209              --        905,226 
Net loss                 --       --            --     (17,559,465)   (17,559,465) 
                 ----------   ------   -----------    ------------    ----------- 
Balance -- 
 March 31, 
 2025            33,191,622   33,191   680,848,800    (658,441,500)    22,440,491 
                 ----------   ------   -----------    ------------    ----------- 
Stock-based 
 compensation            --       --     3,448,453              --      3,448,453 
ATM Expenses             --       --       (73,021)             --        (73,021) 
Net loss                 --       --            --      (9,866,442)    (9,866,442) 
                 ----------   ------   -----------    ------------    ----------- 
Balance -- June 
 30, 2025        33,191,622   33,191   684,224,232    (668,307,942)    15,949,481 
Stock-based 
 compensation            --       --     3,607,554              --      3,607,554 
Net loss                 --       --            --     (10,091,496)   (10,091,496) 
                 ----------   ------   -----------    ------------    ----------- 
Balance -- 
 September 30, 
 2025            33,191,622  $33,191  $687,831,786   $(678,399,438)  $  9,465,539 
                 ==========   ======   ===========    ============    =========== 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment